FDA approves Alcon's Simbrinza for glaucoma and ocular hypertension

04/22/2013 | RTT News

Novartis unit Alcon obtained approval from the FDA to market Simbrinza Suspension, a fixed-dose combination of Brinzolamide and Brimonidine Tartrate, for the reduction of elevated intraocular pressure in patients suffering from primary open-angle glaucoma or ocular hypertension. The approval makes Simbrinza the first fixed-dose glaucoma combo treatment in the U.S. that doesn't contain a beta blocker.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD